Bemis Co Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Bemis Co Inc (BMS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Bemis Co Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 4,064M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (-1.4% annualized vs trailing 12 months).
- Peer revenue share: Bemis Co Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BMS Sales vs. its Competitors, Q1 2019
Bemis Co Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Paper & Paper Products industry grew revenue 4.3% year over year, combined, vs -2.5% for Bemis Co Inc. Bemis Co Inc's share of combined industry revenue moved from 2.96% to 2.77%, a loss of 0.19 percentage points.
Bemis Co Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Bemis Co Inc | Yes | No | Yes | No |
| High-Confidence Competitors (20) | ||||
| Similar Growth & Profitability (8) | 75.00 % (6 of 8) | 62.50 % (5 of 8) | 62.50 % (5 of 8) | 37.50 % (3 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BMS Stock Performance relative to its Competitors
BMS Stock Performance relative to High-Confidence Competitors
BMS Stock Performance relative to Similar Growth & Profitability Competitors
Bemis Co Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Schrodinger Inc | Named by the company | 85% |
| Agenus Inc | Named by the company | 85% |
| Cytosorbents Corporation | Named by the company | 85% |
| Kura Oncology Inc | Named by the company | 85% |
| Protagonist Therapeutics inc | Named by the company | 85% |
| Urogen Pharma Ltd | Named by the company | 85% |
| Autolus Therapeutics Plc | Named by the company | 85% |
| Exscientia Plc | Named by the company | 85% |
| Nextcure Inc | Named by the company | 85% |
| Seagen Inc | Named by the company | 85% |
| Agios Pharmaceuticals Inc | Named by the company | 85% |
| Altamira Therapeutics Ltd | Named by the company | 85% |
| Liminatus Pharma Inc | Named by the company | 85% |
| Replimune Group Inc | Named by the company | 85% |
| Ayala Pharmaceuticals Inc | Named by the company | 85% |
| Cardiff Oncology Inc | Named by the company | 85% |
| Inventiva S a | Named by the company | 85% |
| Puretech Health Plc | Named by the company | 85% |
| Sutro Biopharma Inc | Named by the company | 85% |
| Agape Atp Corporation | Named by the company | 85% |
| Edgewise Therapeutics inc | Named by the company | 85% |
| Mirati Therapeutics Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Bemis Co Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.